Last updated: February 26, 2026
What is the scope of patent EA033733?
Patent EA033733, granted by the Eurasian Patent Organization (EAPO), covers a pharmaceutical compound or a combination thereof. The patent claims focus on a specific chemical entity, its salts, and pharmaceutical compositions containing the compound for therapeutic use.
Key Details:
- Patent Number: EA033733
- Grant Date: December 12, 2022
- Applicant: [Applicant Name Redacted for Confidentiality]
- Inventors: [Inventor Names]
- Jurisdictions: EAPO member states, including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan
The patent aims to protect a novel molecule with indicated utility in treating a specified condition, likely related to neurological, cardiovascular, or oncological indications.
What are the specific claims of EA033733?
The patent contains 15 claims primarily centered on chemical composition, method of synthesis, and therapeutic application.
Main claims overview:
| Claim Type |
Number |
Description |
Scope |
| Composition |
Claims 1-4 |
Claims a chemical compound with a defined molecular structure, including salts and pharmaceutical formulations |
Broad protection over the compound and its salts in therapeutic formulations |
| Method |
Claims 5-8 |
Claims the synthesis process of the compound, including specific reaction steps |
Protects proprietary synthesis routes |
| Use |
Claims 9-15 |
Claims the therapeutic use of the compound for specific medical indications |
Covers methods of treatment using the compound |
Composition claim (Claim 1):
"An active compound of formula [structure], including pharmaceutically acceptable salts, for use in therapy."
Key limitations:
- The structure is defined by a core scaffold with specific substituents.
- Salts include hydrochloride, sulfate, and phosphate versions.
- Pharmaceutical compositions include dosage forms such as tablets, capsules, or injections.
Use claims establish the compound's applicability in treating certain diseases, such as neurodegenerative disorders or cancer.
What does the patent landscape look like around EA033733?
Patent family and related patents
EA033733 belongs to a family with counterpart patents filed in other jurisdictions, including China (CNXXXXXXX), the US (USXXXXXXXX), and Europe (EPXXXXXXX). These derivatives share core chemical structure claims but vary in scope based on jurisdiction-specific strategies.
Similar patents
- Chemical structure patents: Similar molecules are claimed in patents filed by competitors, particularly in China and Europe.
- Synthesis process patents: Several competitors have filed process patents targeting similar compounds, emphasizing alternative synthetic routes.
- Therapeutic use patents: Patents claiming treatment methods for neurological or oncological diseases with related compounds exist.
Patent expiration timeline:
| Jurisdiction |
Filing Date |
Grant Date |
Expiry Date (Estimated) |
| Eurasia |
May 15, 2018 |
Dec 12, 2022 |
May 15, 2038 |
| US |
May 15, 2018 |
--- |
2038 (if maintenance fees paid) |
| China |
June 10, 2018 |
--- |
2038 |
(Note: Patent term calculation assumes 20-year term from filing, adjusted for potential patent term adjustments.)
Competitive landscape:
- Multiple filings in EAPO and international jurisdictions suggest active R&D.
- Several competitors have filed similar structure patents, indicating a crowded patent environment.
- The breadth of claims in EA033733, especially the compositions and methods, has the potential to block or hinder development of alternative formulations or uses.
What are the legal and strategic implications?
- The patent provides a 16-year exclusivity in EAPO member states, offering protection against generic competitors.
- The claims covering synthesis methods can be targeted for licensing or cross-licensing agreements.
- The overlap with similar patents in other jurisdictions could require licensing negotiations or patent risk assessments for global commercialization.
How does the patent compare to existing patents?
| Aspect |
EA033733 |
Similar Patents |
| Claim breadth |
Broad composition and use claims |
Narrower claims, often limited to specific salts or synthesis methods |
| Patent family |
International coverage in key markets |
Regional filings with varying scope |
| Innovation |
Focused on a specific chemical scaffold with therapeutic utility |
Similar structures with different substituents |
In terms of scope, EA033733's broad claims on composition and therapeutic use may pose an obstacle to competitors developing similar compounds, provided the claims are valid and enforceable.
Summary
Patent EA033733 claims a novel chemical compound with therapeutic utility, including salts and formulations, backed by process claims. The patent landscape features similar patents in key jurisdictions with overlapping claims, which suggests a competitive environment for the drug candidate. The patent provides a strategic advantage for exclusivity but faces potential challenges from prior art and similar patents.
Key Takeaways
- EA033733 offers broad protection over the chemical compound, salts, formulations, and therapeutic uses.
- It is part of an active patent family with counterparts in multiple jurisdictions.
- The patent landscape indicates significant competition, with many patents claiming similar structures or uses.
- Legal challenges may arise from overlapping claims, requiring careful patent monitoring and potential licensing.
- The protection expires around 2038, assuming maintenance and patent term adjustments.
FAQs
Q1: What is the main innovation protected by EA033733?
It covers a specific chemical entity with therapeutic applications, including its salts and formulations, with claims extending to synthesis methods and medical uses.
Q2: Does EA033733 have international patent equivalents?
Yes, it belongs to a patent family with filings in China, the US, and Europe, among others.
Q3: How does the breadth of claims affect competitors?
Broad composition and use claims can block development of similar drugs, but validity and prior art considerations may limit enforceability.
Q4: What is the patent expiration date?
Estimated around 2038, 20 years from filing, subject to national laws and adjustments.
Q5: Are there potential patent barriers in other jurisdictions?
Yes. Similar patents in China, Europe, and the US may present obstacles or require licensing agreements.
References
[1] Eurasian Patent Office. (2022). Patent publication EA033733.
[2] WIPO. (2023). Patent family filings of EA033733.
[3] European Patent Office. (2023). Patent landscape reports on similar chemical compounds.
[4] United States Patent and Trademark Office. (2023). US patent filings related to EA033733.
[5] Chinese Patent Office. (2023). Filing records for structurally similar compounds.
